- Janssen Pharmaceutical (NYSE:JNJ) unit Crucell Hollland B.V. awards a subcontract valued at $9M over five years to Bavarian Nordic A/S (OTCPK:BVNRY) to improve the manufacturing process and establish long-term storage of MVA-BN Filo bulk vaccine. The subcontract is part of BARDA's (U.S. Biomedical Advanced Research and Development Authority) contract with Janssen to support the advanced development and manufacturing of the Ebola prime-boost vaccine regimen of Bavarian's MVA-BN Filo and Janssen's Ad26.ZEBOV.
- The subcontract also includes options for an additional $24M to implement process development activities for formulation of a final drug product with a longer shelf life.
- To date, Bavarian has produced and delivered the bulk equivalent of over 1M doses of its vaccine to support clinical trials in Europe and Africa.
- Bavarian will recognized the majority of the revenue from the subcontract in 2016 and 2017.